Terry Smith, MD
Sports Medicine · Birmingham, ALNPI 1447694823
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,928 of the $6,845 with a category attached, or 86.6%. Smith+Nephew accounts for 86.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $6,155 and has fallen 97.9% since, to $127 in 2025.
Across 36 payments — averaging $190.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$6K
- Bioventus LLC$277
- Innovation Technologies Inc$144
- Amgen$121
- Bristol Myers Squibb$112
- Pacira Therapeutics, Inc.$60
- plus $191 from 8 others
What the payments were for
- Food & beverage$91713%
- Education$5,92887%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 2 | $5,941 |
| Bioventus LLC | 7 | $277 |
| Innovation Technologies Inc | 1 | $144 |
| Amgen(2 entities) | 7 | $121 |
| Bristol Myers Squibb | 5 | $112 |
| Pacira Therapeutics, Inc. | 2 | $60 |
| Ferring Pharmaceuticals Inc. | 4 | $56 |
| Abbott | 2 | $34 |
| DJO, LLC | 1 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Zimmer Biomet | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,845 in reported general payments places this provider in the 60th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 34 | $5,570 |
| Halobetasol Propionate | 25 | $4,888 |
| Celecoxib | 56 | $1,197 |
| Baclofen | 21 | $328 |
| Diclofenac Sodium | 29 | $290 |
| Gabapentin | 16 | $85 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 14 | $78 |
| Meloxicam | 17 | $69 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Birmingham
- Edward CainBirmingham$12.7M
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Christoper GarrettBirmingham$58K
- Reaves CrabtreeBirmingham$47K
- David AdkisonBirmingham$46K
- Amir ShahienBirmingham$45K
- Christopher CarterBirmingham$42K
- Christian MerrillBirmingham$40K
- Thomas EvelyBirmingham$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.